About chornixadm

This author has not yet filled in any details.
So far chornixadm has created 24 blog entries.

Combining Genome Change Index (GCI) and liquid biopsy to predict and monitor therapeutic responses.

Ekkehard Schütz, Julia Beck, Donald Peter Braun, Howard B. Urnovitz , et al. Combining Genome Change Index (GCI) and liquid biopsy to predict and monitor therapeutic responses.J Clin Oncol 33, 2015 (suppl; abstr e22020) .

Genomic instability of tumor cells has been associated with a poor prognosis. However, impaired DNA repair pathways leading to genomic instability are also described to increase tumor sensitivity to DNA damaging agents. A comprehensive Genomic Change Index (GCI) as an indicator of defective DNA repair is proposed as a potential predictor of cytotoxic chemotherapy (chemo) response.

By | November 2nd, 2016|Other publications|0 Comments

Quantifying copy number variations in cell-free DNA for potential clinical utility from a large prostate cancer cohort.

Ekkehard Schütz, Howard B. Urnovitz, et al. Quantifying copy number variations in cell-free DNA for potential clinical utility from a large prostate cancer cohort J Clin Oncol 31, 2013 (suppl; abstr 5072).

Prostate cancer (PrCa) is the most frequent non-dermatological malignancy in the male population. Genomic instability resulting in copy number variation (CNV) is a hallmark of malignant transformation.

By | November 2nd, 2016|Other publications|0 Comments

Chronix Biomedical – Our Technology

#TheTurningPointInCancerFight

By | November 2nd, 2016|Video|0 Comments

New Chronix Liquid Biopsy Test Could Save Doctors On Immunotherapy Costs

Chronix Biomedical

Offering around a month from now its circulating cell-free tumour DNA-based test to monitor.....

By | March 27th, 2015|Chronix news|0 Comments